Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2026-04-22 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司控股子公司签订租赁合同暨关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a sponsor (中信证券股份有限公司) regarding the review and verification of a related-party transaction involving a lease contract signed by a controlling subsidiary of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It includes comprehensive information about the related parties, transaction details, pricing, necessity, impact on the company, and the internal approval process including board and independent directors' opinions. The document is not a financial report, earnings release, or regulatory announcement but a formal audit or verification opinion on a specific related-party transaction. It does not announce voting results or changes in management, nor is it a proxy or presentation. The document length (4702 characters) and content indicate it is a standalone audit or verification report on a related-party transaction, fitting the category of Audit Report / Information (AR). Q2 2026
2026-04-22 Chinese
神州细胞2025年度独立董事述职报告（王晓川）
Management Reports Classification · 95% confidence The document is titled as the "2025年度独立董事述职报告" which translates to "2025 Annual Independent Director's Work Report." It details the independent director's duties, attendance at board and committee meetings, communication with auditors, and oversight activities during the year 2025. The content focuses on the independent director's report on their performance and observations rather than the full annual financial report or audit report. It is a specific report by an independent director summarizing their work and opinions for the year, which fits the category of a Management Report or Management-related report. It is not an Annual Report (10-K), Audit Report (AR), or Regulatory Filing (RNS). The document length is about 4036 characters, which is substantial and contains detailed narrative and evaluation, not just an announcement or certification. Therefore, the best fitting category is Management Reports (MDA).
2026-04-22 Chinese
神州细胞2025年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2025年度董事会审计委员会履职情况报告" which translates to the "2025 Annual Report on the Board Audit Committee's Performance." It details the composition, meetings, supervision of external auditors, internal audit guidance, review of financial reports, and oversight of related party transactions and capital increases. The content focuses on the audit committee's activities and their role in overseeing financial reporting and internal controls for the year 2025. It is not a full annual report (10-K) but a specific report on the audit committee's duties and performance. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report describing audit committee activities, audit supervision, and internal control evaluation. The document length is under 5,000 characters but contains substantive content, not just an announcement or certification. Therefore, it should be classified as AR with high confidence. FY 2025
2026-04-22 Chinese
神州细胞关于2026年度申请综合授信额度并提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding the application for a comprehensive credit line and provision of guarantees for its subsidiary. It details the credit amount, guarantee amount, internal approvals, financial data of the subsidiary, and the rationale for the guarantee. The document is a formal public announcement about financing and guarantee arrangements, not a financial report or audit report. It does not contain full financial statements or detailed financial analysis but focuses on the credit and guarantee update. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is about 2804 characters, which is consistent with an announcement rather than a full report.
2026-04-22 Chinese
神州细胞2025年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for the fiscal year 2025 of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It contains detailed auditor opinions, audit basis, key audit matters, and extensive financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes. The presence of auditor signatures and detailed audit procedures confirms this is a standalone audit report. The document length is substantial (15,000 characters), and it contains actual financial data and audit findings, not just an announcement or certification. Therefore, it fits the category of Audit Report / Information (AR). FY 2025
2026-04-22 Chinese
神州细胞2026年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2026 first extraordinary general meeting (临时股东会) of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It includes the meeting date, attendance, voting results on multiple proposals related to issuance of H shares and listing on the Hong Kong Stock Exchange, amendments to company governance documents, and other corporate matters. The document is a formal disclosure of the voting results of shareholder resolutions at a general meeting. It is not a full annual or interim report, nor a management discussion, nor a call transcript. It is not a proxy solicitation or a remuneration report. The key feature is the official announcement of voting results at a shareholders meeting. Therefore, the document fits the category "Declaration of Voting Results & Voting Rights Announcements (DVA)".
2026-04-20 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.